MA55717A - Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3 - Google Patents

Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3

Info

Publication number
MA55717A
MA55717A MA055717A MA55717A MA55717A MA 55717 A MA55717 A MA 55717A MA 055717 A MA055717 A MA 055717A MA 55717 A MA55717 A MA 55717A MA 55717 A MA55717 A MA 55717A
Authority
MA
Morocco
Prior art keywords
psma
antibody
treatment
methods
prostate cancer
Prior art date
Application number
MA055717A
Other languages
English (en)
Inventor
Theresa Mcdevitt
Shoba Shetty
Hong Xie
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55717A publication Critical patent/MA55717A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
MA055717A 2019-04-19 2020-04-17 Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3 MA55717A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962836270P 2019-04-19 2019-04-19

Publications (1)

Publication Number Publication Date
MA55717A true MA55717A (fr) 2022-02-23

Family

ID=70465163

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055717A MA55717A (fr) 2019-04-19 2020-04-17 Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3

Country Status (13)

Country Link
US (1) US11591395B2 (fr)
EP (1) EP3956022A1 (fr)
JP (1) JP2022529985A (fr)
KR (1) KR20220002899A (fr)
CN (1) CN113747944A (fr)
AR (1) AR118720A1 (fr)
AU (1) AU2020259404A1 (fr)
BR (1) BR112021020532A2 (fr)
CA (1) CA3136888A1 (fr)
MA (1) MA55717A (fr)
MX (1) MX2021012767A (fr)
TW (1) TW202104265A (fr)
WO (1) WO2020212947A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240059789A1 (en) * 2021-01-28 2024-02-22 Janssen Biotech, Inc. Psma binding proteins and uses thereof
WO2023164510A1 (fr) 2022-02-23 2023-08-31 Xencor, Inc. Anticorps anti-cd28 x anti-psma
WO2023224912A1 (fr) * 2022-05-16 2023-11-23 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer de la prostate métastatique résistant à la castration avec des anticorps anti-cd3 et anti-psma bispécifiques seuls ou en combinaison avec des anticorps anti-pd-1

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1015576B1 (fr) 1997-09-16 2005-05-04 Egea Biosciences, LLC Synthese chimique complete et synthese de genes et de genomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2004006955A1 (fr) 2001-07-12 2004-01-22 Jefferson Foote Anticorps super humanises
SI1482932T1 (sl) 2002-03-13 2010-02-26 Array Biopharma Inc N3-alkilirani derivati benzimidazola kot inhibitorji mek
RS20181002A1 (sr) 2003-05-30 2018-12-31 Genentech Inc Tretman sa anti-vegf antitelima
CA2523716C (fr) 2003-05-31 2014-11-25 Micromet Ag Molecules humaines de liaison a cd3 anti-humain
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
PL1687066T3 (pl) 2003-11-14 2013-01-31 Brigham & Womens Hospital Inc Sposoby modulowania odporności
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
PT2298768E (pt) 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007004415A1 (fr) 2005-07-01 2007-01-11 Murata Manufacturing Co., Ltd. Substrat céramique à couches multiples, procédé pour le fabriquer et feuille verte composite pour la fabrication dudit substrat
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2008024725A1 (fr) 2006-08-21 2008-02-28 Genentech, Inc. Composés aza-benzofuranyle et leurs procédés d'utilisation
EP2069401A4 (fr) 2007-07-31 2011-02-23 Medimmune Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2706571C (fr) 2007-12-19 2012-11-27 Genentech, Inc. 5-anilinoimidazopyridines et procedes d'utilisation
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
CA2730106A1 (fr) 2008-07-08 2010-01-14 Intellikine, Inc. Inhibiteurs de kinases et procedes d'utilisation
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
CA2738565C (fr) * 2008-10-01 2023-10-10 Micromet Ag Anticorps monocatenaire bispecifique psmaxcd3, specifique d'especes croisees
WO2010045340A1 (fr) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Procédés d’humanisation et de maturation d’affinité d’anticorps
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
EA201201435A1 (ru) 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP2855531A1 (fr) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Anticorps multispécifiques
SI2922872T1 (sl) 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
RS60443B1 (sr) 2013-12-17 2020-07-31 Genentech Inc Anti-cd3 antitela i postupci upotrebe
EP2930188A1 (fr) 2014-04-13 2015-10-14 Affimed Therapeutics AG Molécule de liaison à l'antigène trifonctionnel
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
PT3189081T (pt) 2014-09-05 2020-05-25 Janssen Pharmaceutica Nv Agentes de ligação a cd123 e seus usos
EA201792441A2 (ru) 2015-05-06 2018-06-29 Янссен Байотек, Инк. Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
WO2016179518A2 (fr) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP3411404B1 (fr) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
JP2021506842A (ja) 2017-12-18 2021-02-22 ヤンセン バイオテツク，インコーポレーテツド ポリペプチドの放射性標識
CN112368019A (zh) * 2018-05-16 2021-02-12 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
EA202092847A1 (ru) 2018-05-24 2021-04-20 Янссен Байотек, Инк. Антитела к cd3 и их применение
EP3802609A2 (fr) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Agents de liaison psma et utilisations correspondantes
CA3136892A1 (fr) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methodes de traitement du cancer du rein avec un anticorps anti-psma/cd3

Also Published As

Publication number Publication date
AR118720A1 (es) 2021-10-27
AU2020259404A1 (en) 2021-09-23
US11591395B2 (en) 2023-02-28
KR20220002899A (ko) 2022-01-07
CA3136888A1 (fr) 2020-10-22
CN113747944A (zh) 2021-12-03
TW202104265A (zh) 2021-02-01
MX2021012767A (es) 2021-11-18
WO2020212947A1 (fr) 2020-10-22
US20210040209A1 (en) 2021-02-11
EP3956022A1 (fr) 2022-02-23
JP2022529985A (ja) 2022-06-27
BR112021020532A2 (pt) 2022-03-15

Similar Documents

Publication Publication Date Title
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA55717A (fr) Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
MA44146A (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
RS62274B1 (sr) Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
MA56212A (fr) Compositions et méthodes de traitement du cancer
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201892487A1 (ru) Способ получения соединения диарилтиогидантоина
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA46361A (fr) Traitement du cancer de la prostate
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
EA201591514A1 (ru) Антитела к пан-хемокинам подсемейства elrcxc
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA45780A (fr) Méthodes de traitement du cancer de la prostate
MA47811A (fr) Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин